A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform

Abstract A plague vaccine with a fusion cassette of YscF, F1, and LcrV encoding genes in an adenovirus-5 vector (rAd5-YFV) is evaluated for efficacy and immune responses in mice. Two doses of the vaccine provides 100% protection when administered intranasally against challenge with Yersinia pestis C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paul B. Kilgore, Jian Sha, Jourdan A. Andersson, Vladimir L. Motin, Ashok K. Chopra
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5455c5fff7c646eb8ffc606303806caf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5455c5fff7c646eb8ffc606303806caf
record_format	dspace
spelling	oai:doaj.org-article:5455c5fff7c646eb8ffc606303806caf2021-12-02T14:16:48ZA new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform10.1038/s41541-020-00275-32059-0105https://doaj.org/article/5455c5fff7c646eb8ffc606303806caf2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41541-020-00275-3https://doaj.org/toc/2059-0105Abstract A plague vaccine with a fusion cassette of YscF, F1, and LcrV encoding genes in an adenovirus-5 vector (rAd5-YFV) is evaluated for efficacy and immune responses in mice. Two doses of the vaccine provides 100% protection when administered intranasally against challenge with Yersinia pestis CO92 or its isogenic F1 mutant in short- or long- term immunization in pneumonic/bubonic plague models. The corresponding protection rates drop in rAd5-LcrV monovalent vaccinated mice in plague models. The rAd5-YFV vaccine induces superior humoral, mucosal and cell-mediated immunity, with clearance of the pathogen. Immunization of mice with rAd5-YFV followed by CO92 infection dampens proinflammatory cytokines and neutrophil chemoattractant production, while increasing Th1- and Th2-cytokine responses as well as macrophage/monocyte chemo-attractants when compared to the challenge control animals. This is a first study showing complete protection of mice from pneumonic/bubonic plague with a viral vector-based vaccine without the use of needles and the adjuvant.Paul B. KilgoreJian ShaJourdan A. AnderssonVladimir L. MotinAshok K. ChopraNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Paul B. Kilgore Jian Sha Jourdan A. Andersson Vladimir L. Motin Ashok K. Chopra A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform
description	Abstract A plague vaccine with a fusion cassette of YscF, F1, and LcrV encoding genes in an adenovirus-5 vector (rAd5-YFV) is evaluated for efficacy and immune responses in mice. Two doses of the vaccine provides 100% protection when administered intranasally against challenge with Yersinia pestis CO92 or its isogenic F1 mutant in short- or long- term immunization in pneumonic/bubonic plague models. The corresponding protection rates drop in rAd5-LcrV monovalent vaccinated mice in plague models. The rAd5-YFV vaccine induces superior humoral, mucosal and cell-mediated immunity, with clearance of the pathogen. Immunization of mice with rAd5-YFV followed by CO92 infection dampens proinflammatory cytokines and neutrophil chemoattractant production, while increasing Th1- and Th2-cytokine responses as well as macrophage/monocyte chemo-attractants when compared to the challenge control animals. This is a first study showing complete protection of mice from pneumonic/bubonic plague with a viral vector-based vaccine without the use of needles and the adjuvant.
format	article
author	Paul B. Kilgore Jian Sha Jourdan A. Andersson Vladimir L. Motin Ashok K. Chopra
author_facet	Paul B. Kilgore Jian Sha Jourdan A. Andersson Vladimir L. Motin Ashok K. Chopra
author_sort	Paul B. Kilgore
title	A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform
title_short	A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform
title_full	A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform
title_fullStr	A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform
title_full_unstemmed	A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform
title_sort	new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5455c5fff7c646eb8ffc606303806caf
work_keys_str_mv	AT paulbkilgore anewgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT jiansha anewgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT jourdanaandersson anewgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT vladimirlmotin anewgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT ashokkchopra anewgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT paulbkilgore newgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT jiansha newgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT jourdanaandersson newgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT vladimirlmotin newgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform AT ashokkchopra newgenerationneedleandadjuvantfreetrivalentplaguevaccineutilizingadenovirus5nanoparticleplatform
_version_	1718391666688131072

A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform

Ejemplares similares